A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

• ClinicalTrials.gov Identifier: NCT02864082
• Recruitment Status: Completed
• First Posted: August 11, 2016
• Results First Posted: September 2, 2021
• Last Update Posted: September 29, 2021
• Sponsor: Patagonia Pharmaceuticals, LLC
• Information provided by (Responsible Party): Patagonia Pharmaceuticals, LLC

Study Description

Brief Summary:

Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin. Treatment options include keratolytic agents, which can abruptly lead to extensive shedding or peeling of scales. PAT-001 primarily acts as a keratolytic agent; thus, making it a potential drug candidate for the treatment of skin disorders associated with hyperkeratinization, such as CI. The current study intends to evaluate the safety and tolerability of PAT-001 in patients with CI of either the Lamellar or X-Linked subtypes.

Condition or disease	Intervention/treatment	Phase
Congenital Ichthyosis	Drug: PAT-001, 0.1%; Drug: PAT-001, 0.2%; Drug: Vehicle for PAT-001 0.1%; Drug: Vehicle for PAT-001 0.2%	Phase 2

Detailed Description:

The management of CI is a life-long endeavor, which remains largely symptomatic (i.e., emollients with or without keratolytics agents) and commonly focused on reducing scaling and/or skin lubrication with both systemic and topical treatments. A first-line therapy includes hydration and lubrication accomplished by creams and ointments containing low concentrations of salt, urea, or glycerol, which increase the water-binding capacity of the horny layer. Addition of keratolytics agents are used to decrease corneocyte cohesiveness, to promote desquamation, and to dissolve keratins and lipids (e.g., α-hydroxy acids, salicylic acid, high dose urea, propylene glycol, N-acetylcysteine, and retinoids). Systemic retinoid treatment is reserved for those patients refractory to topical agents because of long-term adverse effects and teratogenicity.

This is a two part, Phase 2, multicenter, proof-of-concept (POC) study of the safety and tolerability of PAT-001 for the treatment of Congenital ichthyosis (CI) in patients ages 12 years of age and older. Part 1 will be a double-blind, randomized, vehicle controlled, bilateral comparison of two treatments (PAT-001 [0.1% or 0.2%] vs. vehicle) for eight (8) weeks.

Part 2 will be a double-blind, active only treatment comparison of the two PAT-001 concentrations (0.1% or 0.2%) for an additional four (4) weeks. Subjects will have the option to participate in the pharmacokinetics (PK) portion of the study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 19 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis
• Actual Study Start Date: March 8, 2017
• Actual Primary Completion Date: February 13, 2018
• Actual Study Completion Date: December 4, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: PAT-001 0.1%; Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.	Drug: PAT-001, 0.1%; PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.; Other Name: PAT-001
Experimental: PAT-001 0.2%; Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.	Drug: PAT-001, 0.2%; PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.; Other Name: PAT-001
Placebo Comparator: Vehicle for PAT-001 0.1% arm; Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.	Drug: Vehicle for PAT-001 0.1%; Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.; Other Name: Vehicle
Placebo Comparator: Vehicle for PAT-001 0.2% arm; Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.	Drug: Vehicle for PAT-001 0.2%; Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.; Other Name: Vehicle

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) [ Time Frame: Day 0 through Day 57 (Weeks 0-8) ]
   The number of participants with AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.
2. Incidence of Local Skin Reactions (LSRs) in Participants Treated With PAT-001 0.1%, 0.2% and/or Vehicle [ Time Frame: Up to Day 84 (Weeks 0-12) ]
   LSRs including burning/stinging, pain, and pruritus (itch) will be assessed in each Treatment Area using a four-point ordinal scale where 0=none, 1=mild, 2=moderate, and 3=severe (based on the investigator's evaluation of the skin reaction) at each clinic visit to allow a comparison between Treatment Groups and Test Articles. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding or reduction in dosing frequency of the test articles will be documented in this LSR Table. Any LSRs that are not listed here will be recorded as AEs.

Secondary Outcome Measures :

1. Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1) [ Time Frame: Up to Day 57 ]
   Overall severity of ichthyosis will be graded using a five-point scale Investigator Global Assessment (IGA) based upon a 5 point scale going from 0=clear., 1=almost clear, 2=mild, 3=moderate to 4=severe. Scoring is based upon investigator evaluation. This is a static morphological scale that refers to a point in time and not a comparison to Baseline.
2. Number of Participants Achieving an Improvement of at Least 1 Point Score in the Individual Clinical Signs/Symptoms of Erythema, Scaling, Fissuring and Papulation/Lichenification Using a Five-point Scale [ Time Frame: Up to Day 57 (Weeks 0-8) ]
   Overall severity of erythema (redness), scaling , fissuring (cracks in skin), and papulation/lichenification (skin thickening, increased pigmentation and/or exaggerated skin lines, formation of papules) will be graded using a five-point scale from 0=clear, 1=almost clear, 2=mild, 3=moderate to 4=severe. This is a static morphological scale that refers to a point in time and not a comparison to Baseline. This scoring is based upon investigator discretion.

Other Outcome Measures:

1. Pharmacokinetics of PAT-001 0.1% and 0.2% at Different Timepoints [ Time Frame: Day 1 (0,1, 2, 3, and 4 hours post Dose) ]
   Serum concentrations for PAT-001 0.1% and PAT-001 0.2% looking at blood levels obtained at timepoints outlined

Eligibility Criteria

• Ages Eligible for Study: 12 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients of either sex aged 12 years or older.
• Females of childbearing potential should use appropriate contraception. Women of childbearing potential must have a negative pregnancy test at screening and baseline visits.
• Patient and legal representative(s), if applicable, has provided written informed consent.
• Patient has congenital ichthyosis of either lamellar or X-Linked subtype.
• Patient has two contralateral comparable Treatment Areas (e.g., each arm is affected and treatments areas can be applied equally).
• Patient is, except for their ichthyosis, in good general health.

Exclusion Criteria:

• Patient is pregnant or breast feeding, or is planning to become pregnant during the study.
• Patient has inflammatory skin disease unrelated to ichthyosis.
• Patient is currently using concomitant retinoid therapy, within two weeks (topical) or 12 weeks (oral) of Visit 2/Baseline.
• Patient is currently taking concomitant immunosuppressive drugs, including systemic corticosteroids, within two weeks of Visit 2/Baseline.
• Patient is currently enrolled in an investigational drug or device study.
• Patient has used an investigational drug or investigational device treatment within 30 days prior to Visit 2/Baseline.
• Patient is unable to communicate or cooperate with the investigator due to language problems, impaired cerebral function, or physical limitations.
• Patient is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

Contacts and Locations

Locations

United States, California

TCR Medical Corporation

San Diego, California, United States, 92123

United States, Connecticut

Yale Center for Clinical Investigation

New Haven, Connecticut, United States, 06519

United States, Illinois

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

United States, Pennsylvania

Paddington Testing Co., Inc

Philadelphia, Pennsylvania, United States, 19103

United States, Texas

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States, 78218

Sponsors and Collaborators

Patagonia Pharmaceuticals, LLC

Investigators

• Study Director: Zachary Rome, BS; Sponsor GmbH

  Study Documents (Full-Text)

Documents provided by Patagonia Pharmaceuticals, LLC:

Study Protocol and Statistical Analysis Plan  [PDF] January 6, 2017

More Information

• Responsible Party: Patagonia Pharmaceuticals, LLC
• ClinicalTrials.gov Identifier: NCT02864082
• Other Study ID Numbers: 205-9051-201
• First Posted: August 11, 2016
• Results First Posted: September 2, 2021
• Last Update Posted: September 29, 2021
• Last Verified: September 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Patagonia Pharmaceuticals, LLC:

X-linked, lamellar

Additional relevant MeSH terms:

Ichthyosis; Ichthyosis, Lamellar; Ichthyosiform Erythroderma, Congenital; Skin Abnormalities; Congenital Abnormalities; Infant, Newborn, Diseases; Keratosis; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn